135 related articles for article (PubMed ID: 38627457)
1. Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
Morganti S; Jin Q; Vincuilla J; Buehler R; Ryan S; Stokes S; Parker T; Mittendorf EA; King TA; Weiss A; Partridge AH; Bychkovsky BL; Curigliano G; Tayob N; Lin NU; Garber JE; Tolaney SM; Lynce F
NPJ Breast Cancer; 2024 Apr; 10(1):28. PubMed ID: 38627457
[TBL] [Abstract][Full Text] [Related]
2. Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer-Real-World Data from Two Large German Breast Centers.
Dannehl D; Engler T; Volmer LL; Tegeler CM; Fusshoeller J; Gabrysch E; Eissler K; Seller A; Grischke EM; Hahn M; Gruber I; Schochter F; Pfister K; Veselinovic K; Leinert E; Rack B; Fink V; Janni W; Brucker SY; Hartkopf AD; Schäffler H
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568663
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.
Morganti S; Bychkovsky BL; Poorvu PD; Garrido-Castro AC; Weiss A; Block CC; Partridge AH; Curigliano G; Tung NM; Lin NU; Garber JE; Tolaney SM; Lynce F
Oncologist; 2023 Jul; 28(7):565-574. PubMed ID: 37210568
[TBL] [Abstract][Full Text] [Related]
4. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE; Garber JE; Gelber RD; Yothers G; Taboada M; Ross L; Rastogi P; Cui K; Arahmani A; Aktan G; Armstrong AC; Arnedos M; Balmaña J; Bergh J; Bliss J; Delaloge S; Domchek SM; Eisen A; Elsafy F; Fein LE; Fielding A; Ford JM; Friedman S; Gelmon KA; Gianni L; Gnant M; Hollingsworth SJ; Im SA; Jager A; Jóhannsson ÓÞ; Lakhani SR; Janni W; Linderholm B; Liu TW; Loman N; Korde L; Loibl S; Lucas PC; Marmé F; Martinez de Dueñas E; McConnell R; Phillips KA; Piccart M; Rossi G; Schmutzler R; Senkus E; Shao Z; Sharma P; Singer CF; Španić T; Stickeler E; Toi M; Traina TA; Viale G; Zoppoli G; Park YH; Yerushalmi R; Yang H; Pang D; Jung KH; Mailliez A; Fan Z; Tennevet I; Zhang J; Nagy T; Sonke GS; Sun Q; Parton M; Colleoni MA; Schmidt M; Brufsky AM; Razaq W; Kaufman B; Cameron D; Campbell C; Tutt ANJ;
Ann Oncol; 2022 Dec; 33(12):1250-1268. PubMed ID: 36228963
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Olaparib for Patients with
Tutt ANJ; Garber JE; Kaufman B; Viale G; Fumagalli D; Rastogi P; Gelber RD; de Azambuja E; Fielding A; Balmaña J; Domchek SM; Gelmon KA; Hollingsworth SJ; Korde LA; Linderholm B; Bandos H; Senkus E; Suga JM; Shao Z; Pippas AW; Nowecki Z; Huzarski T; Ganz PA; Lucas PC; Baker N; Loibl S; McConnell R; Piccart M; Schmutzler R; Steger GG; Costantino JP; Arahmani A; Wolmark N; McFadden E; Karantza V; Lakhani SR; Yothers G; Campbell C; Geyer CE;
N Engl J Med; 2021 Jun; 384(25):2394-2405. PubMed ID: 34081848
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations.
Zettler CM; De Silva DL; Blinder VS; Robson ME; Elkin EB
JAMA Netw Open; 2024 Jan; 7(1):e2350067. PubMed ID: 38170520
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden.
Polyzoi M; Ekman M; Reithmeier A; Jacob J; Karlsson E; Bertranou E; Linderholm B; Hettle R
Pharmacoecon Open; 2024 Mar; 8(2):277-289. PubMed ID: 38093030
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
Yamauchi H; Toi M; Takayama S; Nakamura S; Takano T; Cui K; Campbell C; De Vos L; Geyer C; Tutt A
Breast Cancer; 2023 Jul; 30(4):596-605. PubMed ID: 37005966
[TBL] [Abstract][Full Text] [Related]
9. All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
Wu HL; Luo ZY; He ZL; Gong Y; Mo M; Ming WK; Liu GY
Br J Cancer; 2023 Feb; 128(4):638-646. PubMed ID: 36564566
[TBL] [Abstract][Full Text] [Related]
10. PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
Gonçalves A; Bertucci A; Bertucci F
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471249
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline
Desai NV; Tan AR
JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
[TBL] [Abstract][Full Text] [Related]
13. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Tung NM; Robson ME; Ventz S; Santa-Maria CA; Nanda R; Marcom PK; Shah PD; Ballinger TJ; Yang ES; Vinayak S; Melisko M; Brufsky A; DeMeo M; Jenkins C; Domchek S; D'Andrea A; Lin NU; Hughes ME; Carey LA; Wagle N; Wulf GM; Krop IE; Wolff AC; Winer EP; Garber JE
J Clin Oncol; 2020 Dec; 38(36):4274-4282. PubMed ID: 33119476
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
Jacot W; Lusque A; Vicier C; Mailliez A; de La Motte Rouge T; Cabel L; Levy C; Patsouris A; Desmoulins I; Uwer L; Thery JC; Robain M; Caron O; Tredan O; Filleron T; Frenel JS; Delaloge S
Br J Cancer; 2022 Nov; 127(11):1963-1973. PubMed ID: 36207609
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Pathogenic Germline
Abe A; Imoto I; Tange S; Nishimura M; Iwasa T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741847
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer and Genetic
Lux MP; Fasching PA
Geburtshilfe Frauenheilkd; 2023 Mar; 83(3):310-320. PubMed ID: 36908286
[TBL] [Abstract][Full Text] [Related]
17. Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study.
Kubo T; Muramatsu J; Arihara Y; Murota A; Ishikawa K; Yoshida M; Nagashima H; Tamura F; Ikeda Y; Usami M; Ono M; Nakamura H; Watanabe D; Shibata T; Kasahara K; Sakurai A; Takada K
Jpn J Clin Oncol; 2024 Jan; 54(1):47-53. PubMed ID: 37791389
[TBL] [Abstract][Full Text] [Related]
18. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
Eikesdal HP; Yndestad S; Elzawahry A; Llop-Guevara A; Gilje B; Blix ES; Espelid H; Lundgren S; Geisler J; Vagstad G; Venizelos A; Minsaas L; Leirvaag B; Gudlaugsson EG; Vintermyr OK; Aase HS; Aas T; Balmaña J; Serra V; Janssen EAM; Knappskog S; Lønning PE
Ann Oncol; 2021 Feb; 32(2):240-249. PubMed ID: 33242536
[TBL] [Abstract][Full Text] [Related]
19. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Robson ME; Tung N; Conte P; Im SA; Senkus E; Xu B; Masuda N; Delaloge S; Li W; Armstrong A; Wu W; Goessl C; Runswick S; Domchek SM
Ann Oncol; 2019 Apr; 30(4):558-566. PubMed ID: 30689707
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study.
Lang N; Ayme A; Ming C; Combes JD; Chappuis VN; Friedlaender A; Vuilleumier A; Sandoval JL; Viassolo V; Chappuis PO; Labidi-Galy SI
Swiss Med Wkly; 2023 Mar; 153():40055. PubMed ID: 37011610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
